
Michael J Strong

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2361103/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Differential immune landscapes in appendicular versus axial skeleton. PLoS ONE, 2022, 17, e0267642.	1.1	2
2	Bone metastasis from glioblastoma: a systematic review. Journal of Neuro-Oncology, 2022, 158, 379-392.	1.4	10
3	Evidence of synergism among three genetic variants in a patient with LMNA-related lipodystrophy and amyotrophic lateral sclerosis leading to a remarkable nuclear phenotype. Molecular and Cellular Biochemistry, 2021, 476, 2633-2650.	1.4	4
4	Dura promotes metastatic potential in prostate cancer through the CXCR2 pathway. Journal of Neuro-Oncology, 2021, 153, 33-42.	1.4	2
5	Robotic-Assisted Spinal Surgery. Neurosurgery Clinics of North America, 2020, 31, 103-110.	0.8	37
6	Tau protein phosphorylation at Thr ¹⁷⁵ initiates fibril formation via accessibility of the Nâ€ŧerminal phosphataseâ€activating domain. Journal of Neurochemistry, 2020, 155, 313-326.	2.1	7
7	Effect of Fenestrated Pedicle Screws with Cement Augmentation in Osteoporotic Patients Undergoing Spinal Fusion. World Neurosurgery, 2020, 143, e351-e361.	0.7	14
8	Three-Dimensional Navigated Lateral Lumbar Interbody Fusion: 2-Dimensional Operative Video. Operative Neurosurgery, 2020, 20, E43-E43.	0.4	0
9	Assessment of viral RNA in idiopathic pulmonary fibrosis using RNA-seq. BMC Pulmonary Medicine, 2020, 20, 81.	0.8	12
10	Synergistic toxicity in an in vivo model of neurodegeneration through the co-expression of human TDP-43M337V and tauT175D protein. Acta Neuropathologica Communications, 2019, 7, 170.	2.4	9
11	Detection of Epstein-Barr Virus Infection in Non-Small Cell Lung Cancer. Cancers, 2019, 11, 759.	1.7	36
12	TDP-43 aggregation inside micronuclei reveals a potential mechanism for protein inclusion formation in ALS. Scientific Reports, 2019, 9, 19928.	1.6	19
13	MiR-105 and miR-9 regulate the mRNA stability of neuronal intermediate filaments. Implications for the pathogenesis of amyotrophic lateral sclerosis (ALS). Brain Research, 2019, 1706, 93-100.	1.1	26
14	RNA and Protein Interactors with TDP-43 in Human Spinal-Cord Lysates in Amyotrophic Lateral Sclerosis. Journal of Proteome Research, 2018, 17, 1712-1729.	1.8	4
15	Cover Image, Volume 177B, Number 1, January 2018. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2018, 177, i.	1.1	Ο
16	OPTN p.Met468Arg and ATXN2 intermediate length polyQ extension in families with C9orf72 mediated amyotrophic lateral sclerosis and frontotemporal dementia. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2018, 177, 75-85.	1.1	12
17	Dysregulation of human NEFM and NEFH mRNA stability by ALS-linked miRNAs. Molecular Brain, 2018, 11, 43.	1.3	26
18	Advances in Neuro-Oncology Imaging Techniques. Ochsner Journal, 2018, 18, 236-241.	0.5	10

#	Article	IF	CITATIONS
19	C9 <i>orf</i> 72 mutations do not influence the tau signature of amyotrophic lateral sclerosis with cognitive impairment (ALSci). Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2017, 18, 549-554.	1.1	2
20	The Ontario Neurodegenerative Disease Research Initiative (ONDRI). Canadian Journal of Neurological Sciences, 2017, 44, 196-202.	0.3	72
21	Amyotrophic lateral sclerosis - frontotemporal spectrum disorder (ALS-FTSD): Revised diagnostic criteria. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2017, 18, 153-174.	1.1	607
22	A Pivotal Randomized Clinical Trial Evaluating the Safety and Effectiveness of a Novel Hydrogel Dural Sealant as an Adjunct to Dural Repair. Operative Neurosurgery, 2017, 13, 204-212.	0.4	18
23	Threonine175, a novel pathological phosphorylation site on tau protein linked to multiple tauopathies. Acta Neuropathologica Communications, 2017, 5, 6.	2.4	17
24	Amyotrophic Lateral Sclerosis, a Multisystem Pathology: Insights into the Role of TNF <i>\hat{I}±</i> . Mediators of Inflammation, 2017, 2017, 1-16.	1.4	45
25	Novel miR-b2122 regulates several ALS-related RNA-binding proteins. Molecular Brain, 2017, 10, 46.	1.3	10
26	The association between human cytomegalovirus and glioblastomas: a review. Neuroimmunology and Neuroinflammation, 2017, 4, 96.	1.4	6
27	Brain Tumors: Epidemiology and Current Trends in Treatment. Journal of Brain Tumors & Neurooncology, 2016, 01, .	0.1	6
28	A comprehensive next generation sequencing-based virome assessment in brain tissue suggests no major virus - tumor association. Acta Neuropathologica Communications, 2016, 4, 71.	2.4	57
29	Pathological tau deposition in Motor Neurone Disease and frontotemporal lobar degeneration associated with TDP-43 proteinopathy. Acta Neuropathologica Communications, 2016, 4, 33.	2.4	33
30	Secreted Oral Epithelial Cell Membrane Vesicles Induce Epstein-Barr Virus Reactivation in Latently Infected B Cells. Journal of Virology, 2016, 90, 3469-3479.	1.5	32
31	Preclinical characterization and safety of a novel hydrogel for augmenting dural repair. Materials Research Express, 2015, 2, 095401.	0.8	10
32	Challenges in the Understanding and Treatment of Amyotrophic Lateral Sclerosis/Motor Neuron Disease. Neurotherapeutics, 2015, 12, 317-325.	2.1	25
33	Latent Expression of the Epstein-Barr Virus (EBV)-Encoded Major Histocompatibility Complex Class I TAP Inhibitor, <i>BNLF2a</i> , in EBV-Positive Gastric Carcinomas. Journal of Virology, 2015, 89, 10110-10114.	1.5	30
34	Thr175-phosphorylated tau induces pathologic fibril formation via GSK3β-mediated phosphorylation of Thr231 inÂvitro. Neurobiology of Aging, 2015, 36, 1590-1599.	1.5	32
35	Cytoplasmic sequestration of FUS/TLS associated with ALS alters histone marks through loss of nuclear protein arginine methyltransferase 1. Human Molecular Genetics, 2015, 24, 773-786.	1.4	42
36	New Noncoding Lytic Transcripts Derived from the Epstein-Barr Virus Latency Origin of Replication, <i>oriP</i> , Are Hyperedited, Bind the Paraspeckle Protein, NONO/p54nrb, and Support Viral Lytic Transcription. Journal of Virology, 2015, 89, 7120-7132.	1.5	46

#	Article	IF	CITATIONS
37	Treatment of recurrent metastatic uterine leiomyosarcoma of the spine: a multimodality approach using resection, radiosurgery, and chemotherapy. Journal of Neurosurgery: Spine, 2015, 23, 607-612.	0.9	8
38	Frontotemporal Dysfunction and Dementia in Amyotrophic Lateral Sclerosis. Neurologic Clinics, 2015, 33, 787-805.	0.8	32
39	High-Throughput RNA Sequencing-Based Virome Analysis of 50 Lymphoma Cell Lines from the Cancer Cell Line Encyclopedia Project. Journal of Virology, 2015, 89, 713-729.	1.5	61
40	Benign Sacral Metastatic Meningioma: A Rare Entity. Ochsner Journal, 2015, 15, 200-2.	0.5	4
41	The emerging role of guanine nucleotide exchange factors in ALS and other neurodegenerative diseases. Frontiers in Cellular Neuroscience, 2014, 8, 282.	1.8	25
42	Comprehensive Luciferase-Based Reporter Gene Assay Reveals Previously Masked Up-Regulatory Effects of miRNAs. International Journal of Molecular Sciences, 2014, 15, 15592-15602.	1.8	19
43	GE-33 * A COMPREHENSIVE ASSESSMENT OF VIRAL TRANSCRIPTS IN DNA- AND RNA-SEQ DATASETS FROM HICH-GRADE GLIOMAS REVEALS NO ASSOCIATION. Neuro-Oncology, 2014, 16, v103-v103.	0.6	0
44	Microbial Contamination in Next Generation Sequencing: Implications for Sequence-Based Analysis of Clinical Samples. PLoS Pathogens, 2014, 10, e1004437.	2.1	159
45	Expanding the Conversation on High-Throughput Virome Sequencing Standards To Include Consideration of Microbial Contamination Sources. MBio, 2014, 5, e01989.	1.8	2
46	RNA-binding proteins as molecular links between cancer and neurodegeneration. Biogerontology, 2014, 15, 587-610.	2.0	45
47	Global Bidirectional Transcription of the Epstein-Barr Virus Genome during Reactivation. Journal of Virology, 2014, 88, 1604-1616.	1.5	57
48	Genetic modifiers in carriers of repeat expansions in the C9ORF72 gene. Molecular Neurodegeneration, 2014, 9, 38.	4.4	63
49	RNA CoMPASS: A Dual Approach for Pathogen and Host Transcriptome Analysis of RNA-Seq Datasets. PLoS ONE, 2014, 9, e89445.	1.1	38
50	TMEM106B protects C9ORF72 expansion carriers against frontotemporal dementia. Acta Neuropathologica, 2014, 127, 397-406.	3.9	133
51	Ataxin-2 as potential disease modifier in C9ORF72 expansion carriers. Neurobiology of Aging, 2014, 35, 2421.e13-2421.e17.	1.5	74
52	Comprehensive High-Throughput RNA Sequencing Analysis Reveals Contamination of Multiple Nasopharyngeal Carcinoma Cell Lines with HeLa Cell Genomes. Journal of Virology, 2014, 88, 10696-10704.	1.5	87
53	RNA metabolism in ALS: When normal processes become pathological. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2014, 15, 321-336.	1.1	61
54	Analysis of Novel NEFL mRNA Targeting microRNAs in Amyotrophic Lateral Sclerosis. PLoS ONE, 2014, 9, e85653.	1.1	39

#	Article	IF	CITATIONS
55	Altered microRNA expression profile in amyotrophic lateral sclerosis: a role in the regulation of NFL mRNA levels. Molecular Brain, 2013, 6, 26.	1.3	146
56	Rho guanine nucleotide exchange factor is an NFL mRNA destabilizing factor that forms cytoplasmic inclusions in amyotrophic lateral sclerosis. Neurobiology of Aging, 2013, 34, 248-262.	1.5	34
57	Whole-Genome Sequencing of the Akata and Mutu Epstein-Barr Virus Strains. Journal of Virology, 2013, 87, 1172-1182.	1.5	98
58	Detection of a novel frameshift mutation and regions with homozygosis within ARHGEF28 gene in familial amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2013, 14, 444-451.	1.1	31
59	<i>C9ORF72</i> repeat expansions in cases with previously identified pathogenic mutations. Neurology, 2013, 81, 1332-1341.	1.5	84
60	Genetic analysis of SIGMAR1 as a cause of familial ALS with dementia. European Journal of Human Genetics, 2013, 21, 237-239.	1.4	29
61	Differences in Gastric Carcinoma Microenvironment Stratify According to EBV Infection Intensity: Implications for Possible Immune Adjuvant Therapy. PLoS Pathogens, 2013, 9, e1003341.	2.1	140
62	Epstein-Barr Virus and Human Herpesvirus 6 Detection in a Non-Hodgkin's Diffuse Large B-Cell Lymphoma Cohort by Using RNA Sequencing. Journal of Virology, 2013, 87, 13059-13062.	1.5	35
63	Widespread cerebral haemodynamics disturbances occur early in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2012, 13, 202-209.	2.3	23
64	Detection of Murine Leukemia Virus in the Epstein-Barr Virus-Positive Human B-Cell Line JY, Using a Computational RNA-Seq-Based Exogenous Agent Detection Pipeline, PARSES. Journal of Virology, 2012, 86, 2970-2977.	1.5	27
65	Widespread neuronal and glial hyperphosphorylated tau deposition in ALS with cognitive impairment. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2012, 13, 178-193.	2.3	51
66	Longitudinal Changes in Discourse Prouction in Amyotrophic Lateral Sclerosis. Seminars in Speech and Language, 2012, 33, 79-94.	0.5	22
67	Simulation in Neurosurgical Education. Contemporary Neurosurgery, 2012, 34, 1-5.	0.2	5
68	Impaired proteasome function in sporadic amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2012, 13, 367-371.	2.3	54
69	Length of normal alleles of C9ORF72 GGGGCC repeat do not influence disease phenotype. Neurobiology of Aging, 2012, 33, 2950.e5-2950.e7.	1.5	83
70	Ataxin-2 repeat-length variation and neurodegeneration. Human Molecular Genetics, 2011, 20, 3207-3212.	1.4	147
71	Dementia with motor neuron disease. Clinical Neurology, 2011, 51, 935-935.	0.0	0
72	TDPâ€43 and FUS/TLS: sending a complex message about messenger RNA in amyotrophic lateral sclerosis?. FEBS Journal, 2011, 278, 3569-3577.	2.2	26

#	Article	IF	CITATIONS
73	Molecular pathology and genetic advances in amyotrophic lateral sclerosis: an emerging molecular pathway and the significance of glial pathology. Acta Neuropathologica, 2011, 122, 657-671.	3.9	134
74	RNA Metabolism in Neurodegenerative Disease. Current Chemical Biology, 2011, 5, 90-98.	0.2	2
75	NIPPV: Prevalence, Approach and Barriers to Use at Canadian ALS Centres. Canadian Journal of Neurological Sciences, 2010, 37, 54-60.	0.3	38
76	Quantitative phosphoproteomic analysis of neuronal intermediate filament proteins (NFâ€M/H) in Alzheimer's disease by iTRAQ. FASEB Journal, 2010, 24, 4396-4407.	0.2	57
77	The evidence for altered RNA metabolism in amyotrophic lateral sclerosis (ALS). Journal of the Neurological Sciences, 2010, 288, 1-12.	0.3	160
78	Post-transcriptional control of neurofilaments: New roles in development, regeneration and neurodegenerative disease. Trends in Neurosciences, 2010, 33, 27-37.	4.2	84
79	Human low molecular weight neurofilament (NFL) mRNA interacts with a predicted p190RhoGEF homologue (RGNEF) in humans. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2010, 11, 97-103.	2.3	26
80	Characterization of Detergent-Insoluble Proteins in ALS Indicates a Causal Link between Nitrative Stress and Aggregation in Pathogenesis. PLoS ONE, 2009, 4, e8130.	1.1	101
81	The complement factor C5a receptor is upregulated in NFLâ^'/â^' mouse motor neurons. Journal of Neuroimmunology, 2009, 210, 52-62.	1.1	32
82	Divergent patterns of cytosolic TDP-43 and neuronal progranulin expression following axotomy: Implications for TDP-43 in the physiological response to neuronal injury. Brain Research, 2009, 1249, 202-211.	1.1	192
83	Cytosolic TDP-43 expression following axotomy is associated with caspase 3 activation in NFLâ^//â^' mice: Support for a role for TDP-43 in the physiological response to neuronal injury. Brain Research, 2009, 1296, 176-186.	1.1	82
84	Tar DNA binding protein of 43ÅkDa (TDP-43), 14-3-3 proteins and copper/zinc superoxide dismutase (SOD1) interact to modulate NFL mRNA stability. Implications for altered RNA processing in amyotrophic lateral sclerosis (ALS). Brain Research, 2009, 1305, 168-182.	1.1	187
85	Lack of evidence of monomer/misfolded superoxide dismutaseâ€1 in sporadic amyotrophic lateral sclerosis. Annals of Neurology, 2009, 66, 75-80.	2.8	74
86	Tau phosphorylation at threonineâ€175 leads to fibril formation and enhanced cell death: implications for amyotrophic lateral sclerosis with cognitive impairment. Journal of Neurochemistry, 2009, 108, 634-643.	2.1	32
87	Consensus criteria for the diagnosis of frontotemporal cognitive and behavioural syndromes in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2009, 10, 131-146.	2.3	475
88	Upregulation of GSK3β expression in frontal and temporal cortex in ALS with cognitive impairment (ALSci). Brain Research, 2008, 1196, 131-139.	1.1	69
89	Transient middle cerebral artery occlusion induces microglial priming in the lumbar spinal cord: a novel model of neuroinflammation. Journal of Neuroinflammation, 2008, 5, 29.	3.1	27
90	The syndromes of frontotemporal dysfunction in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2008, 9, 323-338.	2.3	126

#	Article	IF	CITATIONS
91	Creutzfeldt-Jakob disease presenting with visual manifestations. Canadian Journal of Ophthalmology, 2008, 43, 591-595.	0.4	21
92	Cerebral haemodynamic changes accompanying cognitive impairment in primary lateral sclerosis. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2008, 9, 359-368.	2.3	15
93	An Aggregate-Inducing Peripherin Isoform Generated through Intron Retention Is Upregulated in Amyotrophic Lateral Sclerosis and Associated with Disease Pathology. Journal of Neuroscience, 2008, 28, 1833-1840.	1.7	64
94	Inhibition of Pin1 Reduces Glutamate-induced Perikaryal Accumulation of Phosphorylated Neurofilament-H in Neurons. Molecular Biology of the Cell, 2007, 18, 3645-3655.	0.9	55
95	Differentiation Between Primary Lateral Sclerosis and Amyotrophic Lateral Sclerosis. Archives of Neurology, 2007, 64, 232.	4.9	123
96	Prognosis of amyotrophic lateral sclerosis with respiratory onset. Journal of Neurology, Neurosurgery and Psychiatry, 2007, 78, 629-631.	0.9	120
97	14-3-3 protein binds to the low molecular weight neurofilament (NFL) mRNA 3′ UTR. Molecular and Cellular Neurosciences, 2007, 34, 80-87.	1.0	37
98	TDP43 is a human low molecular weight neurofilament (hNFL) mRNA-binding protein. Molecular and Cellular Neurosciences, 2007, 35, 320-327.	1.0	308
99	Lack of TDP-43 abnormalities in mutant SOD1 transgenic mice shows disparity with ALS. Neuroscience Letters, 2007, 420, 128-132.	1.0	107
100	Calcium mediated excitotoxicity in neurofilament aggregate-bearing neurons in vitro is NMDA receptor dependant. Journal of the Neurological Sciences, 2007, 256, 39-51.	0.3	49
101	Loss of nitric oxide-mediated down-regulation of NMDA receptors in neurofilament aggregate-bearing motor neurons in vitro: Implications for motor neuron disease. Free Radical Biology and Medicine, 2007, 42, 143-151.	1.3	4
102	Post-transcriptional control of neurofilaments in development and disease. Experimental Cell Research, 2007, 313, 2088-2097.	1.2	37
103	Innate immunity in amyotrophic lateral sclerosis. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2006, 1762, 1083-1093.	1.8	122
104	Activated microglial supernatant induced motor neuron cytotoxicity is associated with upregulation of the TNFR1 receptor. Neuroscience Research, 2006, 55, 87-95.	1.0	26
105	Neuronal tissue-specific ribonucleoprotein complex formation on SOD1 mRNA: Alterations by ALS SOD1 mutations. Neurobiology of Disease, 2006, 23, 342-350.	2.1	16
106	ALS—Not What We Thought. Archives of Neurology, 2006, 63, 319.	4.9	2
107	The Pathobiology of Amyotrophic Lateral Sclerosis: A Proteinopathy?. Journal of Neuropathology and Experimental Neurology, 2005, 64, 649-664.	0.9	175
108	Increasing Peak Expiratory Flow Time in Amyotrophic Lateral Sclerosis. Chest, 2005, 127, 156-160.	0.4	9

#	Article	IF	CITATIONS
109	Tau protein aggregation in the frontal and entorhinal cortices as a function of aging. Developmental Brain Research, 2005, 156, 127-138.	2.1	40
110	Temporal profiles of neuronal degeneration, glial proliferation, and cell death in hNFL(+/+) and NFL(â^'/â^')mice. Glia, 2005, 52, 59-69.	2.5	23
111	Mutant Copper-Zinc Superoxide Dismutase Binds to and Destabilizes Human Low Molecular Weight Neurofilament mRNA. Journal of Biological Chemistry, 2005, 280, 118-124.	1.6	68
112	Primary lateral sclerosis, hereditary spastic paraplegia and amyotrophic lateral sclerosis: Discrete entities or spectrum?. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2005, 6, 8-16.	2.3	64
113	Amyotrophic lateral sclerosis: contemporary concepts in etiopathogenesis and pharmacotherapy. Expert Opinion on Investigational Drugs, 2004, 13, 1593-1614.	1.9	15
114	Activated p38MAPK Is a Novel Component of the Intracellular Inclusions Found in Human Amyotrophic Lateral Sclerosis and Mutant SOD1 Transgenic Mice. Journal of Neuropathology and Experimental Neurology, 2004, 63, 113-119.	0.9	81
115	Sequestration of nNOS in neurofilamentous aggregate bearing neurons in vitro leads to enhanced NMDA-mediated calcium influx. Brain Research, 2004, 1004, 8-17.	1.1	13
116	Intermediate filament steady-state mRNA levels in amyotrophic lateral sclerosis. Biochemical and Biophysical Research Communications, 2004, 316, 317-322.	1.0	32
117	<i>TAU</i> Mutations are not a Predominant Cause of Frontotemporal Dementia in Canadian Patients. Canadian Journal of Neurological Sciences, 2004, 31, 363-367.	0.3	1
118	Toxic motor neuronopathies and neuropathies. Handbook of Clinical Neurophysiology, 2004, , 437-450.	0.0	1
119	NMDA induces NOS 1 translocation to the cell membrane in NGF-differentiated PC 12 cells. Brain Research, 2003, 976, 149-158.	1.1	27
120	The basic aspects of therapeutics in amyotrophic lateral sclerosis. , 2003, 98, 379-414.		79
121	Cognitive impairment, frontotemporal dementia, and the motor neuron diseases. Annals of Neurology, 2003, 54, S20-S23.	2.8	93
122	A neurotoxic peripherin splice variant in a mouse model of ALS. Journal of Cell Biology, 2003, 160, 939-949.	2.3	113
123	Selective Loss of trans-Acting Instability Determinants of Neurofilament mRNA in Amyotrophic Lateral Sclerosis Spinal Cord. Journal of Biological Chemistry, 2003, 278, 26558-26563.	1.6	32
124	Chapter 6 Cognitive Impairment in the Motor Neuron Disorders. Blue Books of Practical Neurology, 2003, 28, 145-cp1.	0.1	0
125	Chapter 13 Role of Microglia in Amyotrophic Lateral Sclerosis. Blue Books of Practical Neurology, 2003, , 341-cp1.	0.1	0
126	Microtubule-associated tau protein positive neuronal and glial inclusions in ALS. Neurology, 2003, 61, 1766-1773.	1.5	76

#	Article	IF	CITATIONS
127	Activated microglia (BV-2) facilitation of TNF-α-mediated motor neuron death in vitro. Journal of Neuroimmunology, 2002, 128, 31-38.	1.1	86
128	Aluminum inhibition of microglial function in vitro. Journal of Trace Elements in Experimental Medicine, 2002, 15, 141-152.	0.8	2
129	Progress in Clinical Neurosciences: The Evidence for ALS as a Multisystems Disorder of Limited Phenotypic Expression. Canadian Journal of Neurological Sciences, 2001, 28, 283-298.	0.3	69
130	Phosphorylation state of the native high-molecular-weight neurofilament subunit protein from cervical spinal cord in sporadic amyotrophic lateral sclerosis. Journal of Neurochemistry, 2001, 76, 1315-1325.	2.1	68
131	Characterization of Neuronal Intermediate Filament Protein Expression in Cervical Spinal Motor Neurons in Sporadic Amyotrophic Lateral Sclerosis (ALS). Journal of Neuropathology and Experimental Neurology, 2000, 59, 972-982.	0.9	161
132	Creatine and coenzyme Q10 in the treatment of ALS. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders: Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases, 2000, 1, S17-S20.	1.4	14
133	A morphological analysis of the motor neuron degeneration and microglial reaction in acute and chronic in vivo aluminum chloride neurotoxicity. Journal of Chemical Neuroanatomy, 2000, 17, 207-215.	1.0	20
134	Neurofilament metabolism in sporadic amyotrophic lateral sclerosis. Journal of the Neurological Sciences, 1999, 169, 170-177.	0.3	53
135	Nitric oxide synthase expression in cervical spinal cord in sporadic amyotrophic lateral sclerosis. European Journal of Cell Biology, 1998, 77, 338-343.	1.6	37
136	Cognition, Language, and Speech in Amyotrophic Lateral Sclerosis: A Review. Journal of Clinical and Experimental Neuropsychology, 1996, 18, 291-303.	0.8	72
137	Sleep-Disordered Breathing in Amyotrophic Lateral Sclerosis. Chest, 1996, 110, 664-669.	0.4	176
138	Comparative study of chronic aluminum-induced neurofilamentous aggregates with intracytoplasmic inclusions of amyotrophic lateral sclerosis. Acta Neuropathologica, 1996, 92, 545-554.	3.9	42
139	Aluminum neurotoxicity: An experimental approach to the induction of neurofilamentous inclusions. Journal of the Neurological Sciences, 1994, 124, 20-26.	0.3	21
140	Dose-Dependent Selective Suppression of Light (NFL) and Medium (NFM) but Not Heavy (NFH) Molecular Weight Neurofilament mRNA Levels in Acute Aluminum Neurotoxicity. Molecular and Cellular Neurosciences, 1994, 5, 319-326.	1.0	16
141	The Neuronal Cytoskeleton in Disorders of Late Onset and Slow Progression. Annals of the New York Academy of Sciences, 1993, 679, 388-393.	1.8	2
142	Chronic Aluminum-Induced Motor Neuron Degeneration: Clinical, Neuropathological and Molecular Biological Aspects. Canadian Journal of Neurological Sciences, 1991, 18, 428-431.	0.3	37
143	Isolation of fetal mouse motor neurons on discontinuous percoll density gradients. In Vitro Cellular & Developmental Biology, 1989, 25, 939-945.	1.0	12
144	Motor unit estimates in the biceps-brachialis in amyotrophic lateral sclerosis. Muscle and Nerve, 1988, 11, 415-422.	1.0	44

9

#	Article	IF	CITATIONS
145	Methods for estimating numbers of motor units in biceps-brachialis muscles and losses of motor units with aging. Muscle and Nerve, 1988, 11, 423-432.	1.0	288
146	Hemiageusia, Hemianaesthesia and Hemiatrophy of the Tongue. Canadian Journal of Neurological Sciences, 1986, 13, 109-110.	0.3	5